Therapeutic Area: Other Immune Biology

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Badros A, et al.
Blood
September 2024
Authors and Affiliates
Ashraf Badros,1 Laahn Foster,2 Larry D. Anderson Jr,3 Chakra P. Chaulagain,4 Erin Pettijohn,5 Andrew J. Cowan,6 Caitlin Costello,7 Sarah Larson,8 Douglas W. Sborov,9 Kenneth H. Shain,10 Rebecca Silbermann,11 Nina Shah,12* Alfred Chung,12 Maria Krevvata,13 Huiling Pei,14 Sharmila Patel,15 Vipin Khare,15 Annelore Cortoos,15 Robin Carson,13 Thomas S. Lin,15 and Peter Voorhees16 1Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, United States; 2Division of Hematology Oncology, University of Virginia, Charlottesville, VA, United States; 3Myeloma, Waldenstrom’s and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, United States; 4Department of Hematology and Oncology, Myeloma and Amyloidosis Program, Cleveland Clinic Florida, Weston, FL, United States; 5Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI, United States; 6Division of Medical Oncology, Fred Hutch Cancer Center/University of Washington, Seattle, WA, United States; 7Moores Cancer Center, University of California San Diego, La Jolla, CA, United States; 8Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States; 9Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States; 10Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, United States; 11Knight Cancer Institute, Oregon Health & Science University, Portland, OR, United States; 12Department of Medicine, University of California San Francisco, San Francisco, CA, United States; 13Janssen Research & Development, LLC, Spring House, PA, United States; 14Janssen Research & Development, LLC, Titusville, NJ, United States; 15Janssen Scientific Affairs, LLC, a Johnson & Johnson company, Horsham, PA, United States; 16Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, United States.

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Touzeau C, et al.
Blood
August 2024
Authors and Affiliates
Cyrille Touzeau (University hospital, France) Amrita Krishnan (City of Hope Comprehensive Cancer Center, United States) Philippe Moreau (Hematology, University Hospital Hôtel-Dieu, France) Aurore Perrot (CHU Toulouse - IUCT Oncopole, France) Saad Usmani (Memorial Sloan Kettering Cancer Center, United States) Salomon Manier (CHU Lille, France) Michele Cavo (Seràgnoli Institute of Hematology; Bologna University School of Medicine, Bologna, Italy, Italy) Carmen Martinez Chamorro (Hospital Universitario Quirón Pozuelo, Spain) Ajay Nooka (Emory University Winship Cancer Institute, United States) Thomas Martin (UCSF, United States) Lionel Karlin (Hôpital Lyon Sud, France) Xavier Leleu (Hopital La Miletrie, France) Nizar Bahlis (Arnie Charbonneau Cancer Institute, University of Calgary, Canada) Britta Besemer (University Hospital of Tuebingen, Germany) Lixia Pei (Janssen R&D, United States) Sarah Stein (Janssen R&D US, United States) Shun Xin Wang Lin (Janssen Research & Development, United States) Danielle Trancucci (Janssen Research & Development, United States) Raluca Verona (Janssen Research & Development, United States) Suzette Girgis (Janssen Research & Development, LLC, United States) Xin Miao (Janssen Research & Development, LLC, United States) Clarissa Uhlar (Janssen R&D, United States) Katherine Chastain (Janssen Research & Development, LLC, United States) Alfred Garfall (University of Pennsylvania, United States)

Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence

Martinez-Lopez J, et al.
Blood Cancer Journal
August 2024
Authors and Affiliates
J. Martinez-Lopez 1,2, N. Lopez-Muñoz 1, A. Chari 2, S. Dorado 3, S. Barrio1, S. Arora2, A. Kumar2, A. Chung2, T. Martin 2 and J. Wolf2 1Hematology Department, Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain. 2Department of Medicine, University of California San Francisco, San Francisco, CA, USA. 3Medical Department, Altum Sequencing, Madrid, Spain.

Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

Suvannasankha A, et al.
Cancer
August 2024
Authors and Affiliates
Attaya Suvannasankha MD1 | Nizar Bahlis MD2 | Suzanne Trudel MSc, MD3 | Katja Weisel MD4 | Christian Koenecke MD5 | Albert Oriol MD, PhD6 | Peter M. Voorhees MD7 | Aranzazu A. Alonso MD8 | Natalie S. Callander MD9 | María‐Victoria Mateos MD, PhD10 | Nishitha Reddy MD11 | Shawn Hakim PhD12 | John LaMacchia MD, PhD13 | Nashita Patel MSc, PhD14 | Danaé Williams MSc12 | Roxanne C. Jewell PhD15 | Xiangdong Zhou PhD12 | Ira Gupta MD16 | Joanna Opalinska MD12 | Ajay K. Nooka MD, MPH, FACP17 1 Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, Indiana, USA 2 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada 3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada 4 University Medical Center Hamburg‐Eppendorf, Hamburg, Germany 5 Hannover Medical School, Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany 6 Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain 7 Levine Cancer Institute, Atrium Health/Wake Forest University School of Medicine, Charlotte, North Carolina, USA 8 Hospital Universitario Quirónsalud Madrid, Madrid, Spain 9 Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA 10Instituto de Investigación Biomédica de Salamanca and Centro de Investigación del Cáncer, Hospital Universitario de Salamanca, Salamanca, Spain 11Merck & Co., Inc, Rahway, New Jersey, USA 12GlaxoSmithKline, Upper Providence, Pennsylvania, USA 13GlaxoSmithKline, Waltham, Massachusetts, USA 14GlaxoSmithKline, Stevenage, UK 15GlaxoSmithKline, Durham, North Carolina, USA 16GlaxoSmithKline, Philadelphia, Pennsylvania, USA 17Winship Cancer Institute, Emory University Hospital, Atlanta, Georgia, USA

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN

Chari A, et al.
Blood Cancer Journal
July 2024
Authors and Affiliates
Ajai Chari 1,22✉, Jonathan L. Kaufman 2, Jacob Laubach 3, Douglas W. Sborov4, Brandi Reeves 5, Cesar Rodriguez1, Rebecca Silbermann6, Luciano J. Costa 7, Larry D. Anderson Jr 8, Nitya Nathwani9, Nina Shah10, Naresh Bumma11, Sarah A. Holstein 12, Caitlin Costello13, Andrzej Jakubowiak 14, Tanya M. Wildes12, Robert Z. Orlowski 15, Kenneth H. Shain16, Andrew J. Cowan17, Huiling Pei18, Annelore Cortoos19, Sharmila Patel19, Thomas S. Lin19, Peter M. Voorhees 20✉, Saad Z. Usmani 21✉ and Paul G. Richardson 1Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2Winship Cancer Institute, Emory University, Atlanta, GA, USA. 3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 4Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. 5University of North Carolina–Department of Medicine–Chapel Hill, Chapel Hill, NC, USA. 6Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. 7University of Alabama at Birmingham, Birmingham, AL, USA. 8Myeloma, Waldenstrӧm’s and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. 9Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 10University of California San Francisco, San Francisco, CA, USA. 11Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 12Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. 13Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. 14University of Chicago Medical Center, Chicago, IL, USA. 15Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 16Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. 17Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA, USA. 18Janssen Research & Development, LLC, Titusville, NJ, USA. 19Janssen Scientific Affairs, LLC, Horsham, PA, USA. 20Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, USA. 21Memorial Sloan Kettering Cancer Center, New York, NY, USA. 22Affiliation at the time of study conduct.

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

Bumma N, et al.
Journal of Clinical Oncology
June 2024
Authors and Affiliates
Naresh Bumma, MD1; Joshua Richter, MD2 ; Sundar Jagannath, MD2 ; Hans C. Lee, MD3 ; James E. Hoffman, MD4; Attaya Suvannasankha, MD5 ; Jeffrey A. Zonder, MD6 ; Mansi R. Shah, MD7 ; Suzanne Lentzsch, MD, PhD8 ; Rachid Baz, MD9 ; Joseph J. Maly, MD10; Swathi Namburi, MD11; Matthew J. Pianko, MD12 ; Jing Christine Ye, MD, MS12; Ka Lung Wu, MD, PhD13 ; Rebecca Silbermann, MD14 ; Chang-Ki Min, MD15; Marie-Christiane Vekemans, MD16; Markus Munder, MD17 ; Ja Min Byun, MD18 ; Joaqu´ın Mart´ınez-Lopez, MD19 ; Kaniel Cassady, PhD20 ; Michelle DeVeaux, PhD20; Dhruti Chokshi, BS20; Anita Boyapati, PhD20; Anasuya Hazra, PhD20; George D. Yancopoulos, MD, PhD20; L. Andres Sirulnik, MD, PhD20; Karen Rodriguez Lorenc, MD20; Glenn S. Kroog, MD20 ; Yariv Houvras, MD, PhD20; and Madhav V. Dhodapkar, MD21 1The Ohio State University Comprehensive Cancer Center, Columbus, OH 2Icahn School of Medicine at Mount Sinai, New York, NY 3The University of Texas MD Anderson Cancer Centre, Houston, TX 4University of Miami Health System, Miami, FL 5Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN 6Karmanos Cancer Institute, Detroit, MI 7Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 8Columbia University Medical Center, New York, NY 9Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL 10Norton Cancer Institute, Louisville, KY 11Swedish Cancer Institute, Seattle, WA 12Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 13Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium 14Knight Cancer Institute, Oregon Health & Science University, Portland, OR 15Department of Hematology, College of Medicine, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea 16Department of Hematology, Cliniques Universitaires Saint-Luc, Universit´e Catholique de Louvain (UCLouvain), Brussels, Belgium 17Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany 18Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea 19Hospital 12 de Octubre, i112, School of Medicine Universidad Complutense, CNIO, Madrid, Spain 20Regeneron Pharmaceuticals, Inc, Tarrytown, NY 21Emory University School of Medicine, Atlanta, GA

Fixed-Duration Pirtobrutinib plus Venetoclax with or without Rituximab inRelapsed/Refractory CLL: Phase 1b BRUIN Trial

Roeker L, et al.
Blood
June 2024
Authors and Affiliates
Lindsey E. Roeker1, Jennifer A. Woyach2, Chan Y. Cheah3, Catherine C. Coombs4, Nirav N. Shah5, William G. Wierda6, Manish R. Patel7, Nicole Lamanna8, Donald E. Tsai9, Binoj Nair9, Chunxiao Wang10, Xiang Zhao9, Dan Liu10, David Radtke10, Sonya Chapman10, Narasimha Marella9, Samuel C. McNeely9, Jennifer R. Brown11 1Memorial Sloan Kettering Cancer Center, New York, NY, USA 2The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA 3Linear Clinical Research, and Sir Charles Gairdner Hospital, and the University of Western Australia, Perth, Australia 4University of California, Irvine, Orange, CA, USA 5Medical College of Wisconsin, Milwaukee, WI, USA 6MD Anderson Cancer Center, Houston, TX, USA 7Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, USA 8Columbia University Medical Center/New York-Presbyterian, New York, NY, USA 9Loxo@Lilly, Indianapolis, IN, USA 10Eli Lilly and Company, Indianapolis, IN, USA 11Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Facon T, et al.
New England Journal of Medicine
June 2024
Authors and Affiliates
Thierry Facon, M.D., Meletios‑Athanasios Dimopoulos, M.D., Xavier P. Leleu, M.D., Meral Beksac, M.D., Ludek Pour, M.D., Roman Hájek, M.D., Zhuogang Liu, M.D., Jiri Minarik, M.D., Philippe Moreau, M.D., Joanna Romejko‑Jarosinska, M.D., Ivan Spicka, M.D., Vladimir I. Vorobyev, M.D., Britta Besemer, M.D., Tadao Ishida, M.D., Wojciech Janowski, M.D., Sevgi Kalayoglu‑Besisik, M.D., Gurdeep Parmar, M.D., Pawel Robak, M.D., Elena Zamagni, M.D., Hartmut Goldschmidt, M.D., Thomas G. Martin, M.D., Salomon Manier, M.D., Mohamad Mohty, M.D., Corina Oprea, M.D., Marie‑France Brégeault, M.D., Sandrine Macé, Ph.D., Christelle Berthou, M.S., David Bregman, M.D., Zandra Klippel, M.D., and Robert Z. Orlowski, M.D., for the IMROZ Study Group Department of Hematology, Centre Hospitalier Universitaire (CHU) de Lille, University of Lille, Lille (T.F., S. Manier), the French National Academy of Medicine (T.F.), and the Department of Hematology, Hôpital Saint-Antoine, Sorbonne University and INSERM (M.M.), Paris, Service d’Hématologie et Thérapie Cellulaire, CHU and Centre d’Investigation Clinique INSERM Unité 1402, Poitiers (X.P.L.), the Department of Hematology, University Hospital Hôtel-Dieu, Nantes (P.M.), and Sanofi, Research and Development, Vitry-sur-Seine (C.O., M.-F.B., S. Macé, C.B.) — all in France; the Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens (M.-A.D.); the Department of Hematology, Ankara University, and the Istinye University Ankara Liv Hospital, Ankara (M.B.), and the Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul (S.K.-B.) — all in Turkey; the Department of Internal Medicine, Hematology, and Oncology, University Hospital Brno, Brno (L.P.), the Department of Hemato-Oncology, University Hospital Ostrava, and the Faculty of Medicine, University of Ostrava, Ostrava (R.H.), the Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacký University and University Hospital Olomouc, Olomouc (J.M.), and the Charles University and General Hospital in Prague, Prague (I.S.) — all in the Czech Republic; Shengjing Hospital of China Medical University, Shenyang, China (Z.L.); the Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw (J.R.-J.), and the Department of General Hematology, Copernicus Memorial Hospital, Comprehensive Cancer Center and Traumatology, Łódź (P.R.) — both in Poland; the S.P. Botkin Moscow City Clinical Hospital, Moscow (V.I.V.); the Department of Hematology, Oncology, Immunology, and Rheumatology, University Hospital of Tübingen, Tübingen (B.B.), and the Department of Internal Medicine V, University of Heidelberg, Heidelberg (H.G.) — both in Germany; the Japanese Red Cross Medical Center, Tokyo (T.I.); Calvary Mater Newcastle, Newcastle, NSW (W.J.), and the Illawarra Cancer Care Centre, Wollongong, NSW (G.P.) — both in Australia; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” and Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy (E.Z.); the Division of Hematology–Oncology, University of California, San Francisco, San Francisco (T.G.M.); Sanofi, Patient Safety and Pharmacovigilance, Bridgewater, NJ (D.B.); Sanofi, Cambridge, MA (Z.K.); and the Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.).

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Leleu X, et al.
Nature Medicine
June 2024
Authors and Affiliates
Xavier Leleu 1,54 , Cyrille Hulin2,54, Jerome Lambert3, Arthur Bobin1, Aurore Perrot 4, Lionel Karlin5, Murielle Roussel6, Lydia Montes7, Brieuc Cherel8, Thomas Chalopin9, Borhane Slama10, Marie-Lorraine Chretien11, Kamel Laribi12, Claire Dingremont13, Christophe Roul14, Clara Mariette15, Sophie Rigaudeau16, Claire Calmettes17, Mamoun Dib18, Mourad Tiab19, Laure Vincent20, Jacques Delaunay21, Alberto Santagostino22, Margaret Macro23, Emmanuelle Bourgeois24, Frederique Orsini-Piocelle25, Julie Gay26, Benoit Bareau27, Noemie Bigot3, François Vergez28, Pierre Lebreton29, Reza Tabrizi30, Agathe Waultier-Rascalou31, Laurent Frenzel32, Ronan Le Calloch33, Emilie Chalayer34, Thorsten Braun35, Florence Lachenal36, Selim Corm37, Celine Kennel38, Rakiba Belkhir39, Jean-Sebastien Bladé40, Bertrand Joly41, Valentine Richez-Olivier42, Helene Gardeney1, Helene Demarquette43, Daniela Robu-Cretu44, Laurent Garderet45, Muriel Newinger-Porte46, Amine Kasmi47, Bruno Royer48, Olivier Decaux49, Bertrand Arnulf48, Karim Belhadj50, Cyrille Touzeau51, Mohamad Mohty52, Salomon Manier53, Philippe Moreau51, Hervé Avet-Loiseau28, Jill Corre 28 & Thierry Facon53 1Hematology, CIC 1082, U1313, CHU, University, Poitiers, France. 2CHU, Bordeaux, France. 3SBIM, Saint-Louis Hospital, Paris, France. 4University Hospital, iUCT Oncopole, Toulouse, France. 5Hôpital Lyon Sud, Pierre-Benite, France. 6Hematology, CHU, Limoges, France. 7Hematology, CHU, Amiens, France. 8CH Bretagne Atlantique, Vannes, France. 9Hematology, CHU, Tours, France. 10Hospital center, Avignon, France. 11Hematology, University Hospital, Inserm U1231, University of Burgundy Franche-Comté, Dijon, France. 12Hematology, CH, Le Mans, France. 13Internal Medicine, Tarbes-Lourdes Hospital, Tarbes, France. 14CH La Rochelle, La Rochelle, France. 15Hematology, CHU, Grenoble, France. 16Hématologie – Le Chesnay, CH Versaille, Paris, France. 17CH, Périgueux, France. 18University Hospital, Angers, France. 19Hematology, CH Departemental de La Roche-sur-Yon, La Roche-sur-Yon, France. 20CHU, Montpellier, France. 21Hôpital privé du confluent 2, Nantes, France. 22Hematology, CH, Troyes, France. 23Hematology, IHBN – CHU, Caen, France. 24GHICL, Lille, France. 25Hématologie, CH, Annecy Genevois, France. 26Hematology, CH de la côte basque, Bayonne, France. 27Hematology, Les Hôpitaux Privés Rennais Cesson Sévigné - Vivalto Santé, Cesson Sévigné, France. 28Unit for Genomics in Myeloma, iUCT Oncopole, Toulouse, France. 29Hematology, CH, Le Havre, France. 30Hematology, CHI de Mont De Marsan, Mont-de-Marsan, France. 31Hematology, CHU, Nîmes, France. 32Hematology, Necker Hospital, Paris, France. 33Hematology, CH de Cornouaille, Quimper Concarneau, Concarneau, France. 34Hematology, CHU, Saint-Etienne, France. 35Hematology, Avicenne hospital APHP, Bobigny, France. 36CH Pierre Oudot, Bourgoin-Jallieu, France. 37Medipole de Savoie, Challes les Eaux, France. 38CH William Morey, Chalon sur Saône, France. 39Rheumatology, Hopital Bicetre, AP-HP, Universite Paris Saclay, Paris, France. 40Onco-Hematology Department, HIA Sainte Anne, Toulon, France. 41CH Sud Francilien, Corbeil Essonnes, France. 42CHU de Nice, Nice, France. 43Hematology, CH, Dunkerque, France. 44Hematology, CH, Lens, France. 45Hopital Pitié Salpetriere, hématologie APHP, Paris, France. 46Hôpital Emile Muller, Mulhouse, France. 47DRC, CHU, Poitiers, France. 48Hôpital Saint-Louis, Paris, France. 49Hematology, UMR U1236, University Hospital, Rennes, France. 50C.H.U. Henri Mondor, Créteil, France. 51Hématologie, CHU Hotel Dieu Université, Nantes, France. 52Hematology, Sorbonne University, Saint-Antoine Hôpital (AP-HP), UMRs 938, Paris, France. 53Hematology, University Hospital Inserm U-S1277 and CNRS UMR9020, Lille, France. 54These authors contributed equally: Xavier Leleu, Cyrille Hulin.

Belantamab Mafodotin, Pomalidomide,and Dexamethasone in Multiple Myeloma

Dimopoulos M, et al.
New England Journal of Medicine
June 2024
Authors and Affiliates
Meletios Athanasios Dimopoulos, M.D., Meral Beksac, M.D., Ludek Pour, M.D., Sosana Delimpasi, M.D., Vladimir Vorobyev, M.D., Hang Quach, M.D., Ivan Spicka, C.Sc., Jakub Radocha, M.D., Ph.D., Pawel Robak, M.D., Ph.D., Kihyun Kim, M.D., Michele Cavo, M.D., Kazuhito Suzuki, M.D., Ph.D., Kristin Morris, Pharm.D., Farrah Pompilus, Ph.D., Amy Phillips‑Jones, M.Sc., Xiaoou L. Zhou, M.D., Ph.D., Giulia Fulci, Ph.D., Neal Sule, M.B., B.S., M.D., Brandon E. Kremer, M.D., Ph.D., Joanna Opalinska, M.D., Ph.D., María‑Victoria Mateos, M.D., Ph.D., and Suzanne Trudel, M.D., for the DREAMM-8 Investigators Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens (M.A.D.), and General Hospital Evangelismos (S.D.) — both in Athens; the Department of Hematology, Ankara Liv Hospital, Istinye University, Ankara, Turkey (M.B.); the Department of Internal Medicine, Hematology, and Oncology, University Hospital Brno, Brno (L.P.), the First Faculty of Medicine, Charles University, and General Hospital, Prague (I.S.), and the Fourth Department of Internal Medicine–Hematology, University Hospital Hradec Králové, and Faculty of Medicine in Hradec Králové, Charles University, Hradec Králové (J.R.) — all in the Czech Republic; Leningrad Regional Clinical Hospital, Saint Petersburg, Russia (V.V.); the University of Melbourne, St. Vincent’s Hospital, Melbourne, VIC, Australia (H.Q.); Medical University of Lodz, Łódź, Poland (P.R.); Sungkyunkwan University and Samsung Medical Center, Seoul, South Korea (K.K.); IRCCS Azienda Ospedaliero–Universitaria di Bologna, Seràgnoli Institute of Hematology, and Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy (M.C.); the Division of Clinical Oncology–Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo (K.S.); GSK, Durham, NC (K.M.); GSK, Philadelphia (F.P.), and GSK, Collegeville (N.S., B.E.K., J.O.) — both in Pennsylvania; GSK, Stevenage, United Kingdom (A.P.-J.); GSK, Waltham, MA (X.L.Z., G.F.); the Hematology Department, Cancer Research Center–Instituto de Investigación Biomédica de Salamanca, University Hospital of Salamanca, Salamanca, Spain (M.-V.M.); and the Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, Toronto (S.T.)